Innate Pharma (OTCMKTS:IPHYF - Get Free Report) is anticipated to release its resultson Wednesday, May 13th. Analysts expect Innate Pharma to post earnings of ($0.3524) per share and revenue of $5.7550 million for the quarter.
Innate Pharma Stock Performance
Shares of IPHYF opened at $1.50 on Wednesday. Innate Pharma has a 52 week low of $1.37 and a 52 week high of $1.50. The firm's 50-day simple moving average is $1.72 and its 200 day simple moving average is $1.95.
Innate Pharma Company Profile
(
Get Free Report)
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company's pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Innate Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.
While Innate Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
